Skip to content

Advertisement

Articles

Page 111 of 113

  1. Content type: Commentary

    The "integrated safety report" of the drug registration files submitted to health authorities usually summarizes the rates of adverse events observed for a new drug, placebo or active control drugs by pooling ...

    Authors: Michel Lièvre, Michel Cucherat and Alain Leizorovicz

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:6

    Published on:

  2. Content type: Research

    Antioxidant supplementation with vitamin E had no effect in the prevention of cardiovascular diseases (CVD) in three recent large, randomized clinical trials. In order to reassess critically the role of vitami...

    Authors: Chiara Chiabrando, Fausto Avanzini, Claudia Rivalta, Fabio Colombo, Roberto Fanelli, Gaetana Palumbo and Maria Carla Roncaglioni

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:5

    Published on:

  3. Content type: Commentary

    The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was the first trial to assess whether statins might be of clinical benefit in those with recently unstable coronary disease. M...

    Authors: Herbert D Aronow

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:3

    Published on:

  4. Content type: Review

    Although diabetes mellitus is predominantly a metabolic disorder, recent data suggest that it is as much a vascular disorder. Cardiovascular complications are the leading cause of death and disability in patie...

    Authors: Prakash C Deedwania

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:2

    Published on:

  5. Content type: Research

    Overweight older adults are often counseled to lose weight, even though there is little evidence of excess mortality in that age group. Overweight and underweight may be more associated with health status than...

    Authors: Paula Diehr, Anne B Newman, Sharon A Jackson, Lewis Kuller and Neil Powe

    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:1

    Published on:

  6. Content type: Commentary

    The treatment of patients with coronary artery disease continues to evolve; all three strategies – medical therapy, surgical revascularization, and percutaneous coronary intervention – have changed. Medical th...

    Authors: David R Holmes Jr

    Citation: Trials 2001 2:263

    Published on:

  7. Content type: Commentary

    This commentary has two purposes: to summarize the rationale, design and initial results of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial; and to provide a hist...

    Authors: Lawrence R Krakoff

    Citation: Trials 2001 2:254

    Published on:

  8. Content type: Review

    The identification of angiogenic growth factors, such as vascular endothelial growth factor and fibroblast growth factor, has fueled interest in using such factors to induce therapeutic angiogenesis. The resul...

    Authors: Yin-Shan Ng and Patricia A D'Amore

    Citation: Trials 2001 2:278

    Published on:

  9. Content type: Research

    The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascula...

    Authors: Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto and Robert H Fagard

    Citation: Trials 2001 2:298

    Published on:

Annual Journal Metrics

Advertisement